<DOC>
	<DOCNO>NCT01011985</DOCNO>
	<brief_summary>To determine type hemodialysis vascular access correlate marker inflammation , namely C-reactive protein interleukin-6 , access patient survival end stage renal disease population .</brief_summary>
	<brief_title>A Study Evaluating Association Inflammation With Hemodialysis Access Type</brief_title>
	<detailed_description>A Study Of The Effect Of Hemodialysis Vascular Access Type On Markers Of Inflammation PI : Michele H. Mokrzycki MD , MS Introduction/Background : The prevalence chronic inflammation high ( 35-65 % ) end stage renal disease ( ESRD ) patient associate increased risk atherosclerosis , overall cardiovascular mortality population . ( 1-4 ) Stenvinkel et al observe pre-HD C-reactive protein ( CRP ) level &gt; 10 associate high prevalence carotid plaque ( p &lt; 0.01 ) , clinical manifestation atherosclerotic cardiovascular disease ( MI , CVA , PVD ) ( p &lt; 0.05 ) ESRD population . ( 1 ) Zimmerman et al report 2.7-fold 4.6-fold high risk 2 yr all-cause mortality associate CRP level 7.5-15.7. &gt; 15.7 , respectively . The cardiovascular mortality similar ( 2.9-fold , 5.5-fold ) . A single elevated CRP level show powerful indicator mortality ESRD patient , even 4-5 year follow-up . ( 3 ) . CRP sensitive major acute phase protein , synthesize hepatocytes transcriptional control IL-6 . In presence human serum , CRP induce expression MCP-1 , VCAM-1 , ICAM-1 , E-selectin . ( 5 ) . The interaction CRP monocytes vitro result release IL-1 β , IL-6 , TNF-α , tissue factor . ( 6 ) The origin inflammation ESRD population unclear , although HD session per se implicate . Korevaar et al studied effect HD session CRP level mortality 186 pt . ( 7 ) Thirty-eight % patient CRP level detection ( &lt; 3 mg/L ) , patient detectable CRP level pre-HD 37 % increase HD , 25 % patient increase ( mean +2.3 ( 0.6-9.2 ) ) CRP level ( adjusted change blood volume ) HD . There difference pre-HD CRP level latter 2 group . A low 2 yr survival observe group CRP increase HD , ( 44 vs. 66 % , p=0.09 ) . After adjust nutritional factor , age , comorbidity primary kidney disease , rise 1 mg/dl CRP HD session , associated increase mortality risk 9 % ( Adjusted hazard ratio 1.09 , 95 % CI=1.09-1.16 ) Independent predictor high CRP level HD include patient age ( β=0.07 , p=0.05 ) , pre-HD CRP ( β=0.95 , p &lt; 0.01 ) , 2 needle dialysis ( β=2.39 , p=0.05 , cholesterol ( ( β= -0.92 , p=0.04 ) . Additional possible reason increase marker inflammation ESRD population include 1 ) uremia-related alteration immune/host defense system , specifically increased cytokine production , 2 ) increase oxidative stress ( oxidized-LDL ) , advance glycation end product ( AGEs ) 3 ) dialysis membrane ( IL-6 IL-1 β production certain membrane ) , 4 ) contaminate dialysate , [ ultrapure dialysate reduces CRP level ] ,5 ) intercurrent clinical event , 6 ) occult arteriovenous graft infection , 7 ) protein-energy malnutrition , 8 ) short time hemodialysis ( HD ) . ( 8-13 ) . None CRP associate mortality study control type vascular access . There report association vascular access type marker inflammation . Kaysen et al report association low level serum albumin presence AVG , Thadani et al recently report elevated WBC count hemocatheters ( 14,15 ) . Polkinghorne et al studied effect vascular access incident hemodialysis patient all-cause mortality use multivariate analysis . ( 16 ) In adjust analysis , catheter use AVGs associate significant excess mortality . Compared AVFs , catheter associate 3.3-fold high AVGs 1.6-fold high all-cause mortality 120 day . However , author speculate , part , may due high risk infection . In fact risk infectious death 1.7-fold high AVGs , 2.7 fold high catheter . The risk type vascular access inflammation , independent infection , unknown . Research Question/Objective : To determine type HD vascular access correlate marker inflammation , namely CRP IL-6 , access patient survival ESRD population . Study Design : A prospective study use multiple group design . Subjects : Incident ESRD patient . Patients Stage IV V ( GFR &lt; 30 ml/min use MDRD mod equation ) recruit renal clinic private practice . Sites include Moses Weiler campuses Montefiore Medical Center Bronx , NY . Type vascular access insert determine clinical ground patient 's nephrologist access surgeon , include hemocatheter , arteriovenous graft , arteriovenous fistula . Study Procedures : Blood sample ( 10 cc ) drawn immediately ( within 24 hour ) prior access surgery , 1 week , 1 , 3 , 6 12 month , upon dialysis initiation . ( 6 sample per subject 1 year ) Once patient hemodialysis blood sample draw pre-HD via access . Samples centrifuge immediately ( 3000 rpm x 10 minute ) , cool within 1 hour , store -80 degree C. Pre-dialysis sample test high-sensitivity C-Reactive Protein ( hsCRP ) TNF-α IL-6 ( ELISA assay , plasma sandwich-type immunoassay ) level . Patient demographic clinical data record , This include age , race , sex , body surface area , DM , SLE connective tissue disease , malignancy , history atherosclerotic disease ( CAD , PVD , CVA ) , active infection , history viral infection hepatitis B C , human immunodeficiency virus . Routine monthly lab result draw pre-dialysis part clinical practice record , include serum albumin , complete blood count , electrolytes , blood urea nitrogen , creatinine , liver function test , lipid profile . Medications review presence ACE-Inhibitors , ARBs , aspirin , NSAIDS , statins . A subjective global assessment score ( SGA ) comorbidity risk score perform . ( 17,18 ) Date HD initiation , type HD membrane record . Clinical event vascular access surgery monitor , include infection , hospitalization ( reason ) , MI , CVA . Outcomes record include access survival ( primary secondary patency ) , patient mortality ( all-cause , infectious cardiovascular ) . Data Management Analysis : Differences hs-CRP , TNF-α IL-6 level 3 vascular access group time period ( baseline , 1 week , 1 , 3 , 6,12 month ) analyze use random effect ( mixed ) model , time random effect . A Power analysis perform Kathrine Freeman , PhD Department Biostatistics Epidemiology Montefiore Medical Center , use multiple comparison group . We hypothesize 100 % increase hsCRP level baseline catheter group 10 % increase AVF group . We predict AVG group increase h CRP 10-100 % . The initial power analysis ( 80 % , 2-tailed α=0.05 ) predict 51 subject per group would need . Anticipating 20 % dropout rate per year , recruit 61 subject require group . All hsCRP data transform , likely use log scale , per prior study upon review distribution data . Dunnett 's multiple comparison procedure perform 2 contrast ( group , ie . AVF AVG group , compare tunnel catheter group . A multivariate analysis use mixed effect model perform determine factor related change CRP level baseline 1 week , 3 , 6 , 12 month . Patient access survival analyze use Kaplan-Meier method Cox proportional hazard regression analysis . Blood specimen store -70 freezer Dr. Joel Neugarten 's lab , Moses 6th floor laboratory . Patient chart cod stored lock file cabinet Dr. Mokrzycki 's office , Centennial 4th floor Montefiore Medical Center . One co-investigators perform sandwich immunoassays hsCRP , TNF-α IL-6 Dr. Victor Schuster 's lab , Ullman Building 6th floor . Implementation plan/timetable : Enrollment subject Dr. Mala Sachdeva , Peter Durkin , PA begin protocol approve IRB . The site patient identification enrollment , baseline specimen Renal Clinics Montefiore Weiler Hospitals , Renal Faculty practice . Follow-up specimen draw site , patient pre-hemodialysis , draw dialysis session patient already receive hemodialysis . Both preliminary follow-up data entry perform Dr. Mala Sachdeva use SPSS . Patient charts/records specimens coded ensure confidentiality . Specimens chart store describe . Data analysis perform Dr. Mokrzycki , Dr. Sachdeva Dr Kathrine Freeman . The anticipated duration study 3 year : approximately 2 year patient enrollment 1 year follow-up data time data analysis .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>CKD patient refer initial vascular access Able consent surgery/study Active inflammatory state Active infection Autoimmune diseases Acute renal allograft rejection HIV positive status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>end stage renal disease</keyword>
	<keyword>inflammation</keyword>
	<keyword>vascular access</keyword>
	<keyword>hemodialysis</keyword>
</DOC>